South African genomics teams are turning benefit sharing into a budget line
South African genomics researchers are presenting a more concrete answer to one of biomedical research’s oldest ethical questions: what do participating communities receive in return when their data and lived experience help drive scientific discovery?
At the World Congress of Bioethics in Johannesburg earlier in July, Ngoni Ngwarai of the SAMRC/Wits Rural Public Health and Health Transitions Research Unit outlined an approach that moves beyond abstract commitments. In projects highlighted in a new Nature Communications paper, research teams directed 10% of their budgets toward benefits chosen by communities themselves rather than by institutions, funders, or outside experts.
That may sound procedural, but it is a notable operational shift. Genomics research has long depended on samples, data, and cooperation from African populations, whose genetic diversity has made major contributions to global understanding of disease and to the development of advanced therapies. Yet communities that participate in research have often seen little direct return from those advances. The South African model attempts to close that gap by treating benefit sharing not as an afterthought, but as part of project design.
How the model differs from standard reimbursement
The distinction the researchers draw is important. Participant reimbursement typically covers practical costs such as travel or time. Community benefit sharing is something else: it allocates resources to priorities identified by the community, with decisions shaped through local consultation and collective choice.
According to the source material, the work presented by Ngwarai draws on real examples from the SABR and ARK projects. Instead of limiting support to individual compensation, project funds were used for community-selected initiatives that included portable generators for schools, water tanks, support for a home for senior citizens, and a community organization focused on youth and health.
Those examples matter because they show the model operating in practice rather than in principle. Ethical language around fairness, reciprocity, and inclusion is common in research governance. What is less common is a clearly defined mechanism that says, in advance, what share of funds will be set aside and how those resources will be governed.
By assigning a fixed portion of project budgets to community-selected uses, the South African projects provide a structure that other institutions can examine, adapt, and test. That gives funders, universities, and private-sector partners something more actionable than a general statement that communities should benefit.
A response to a long-running imbalance in global science
The timing is significant. The World Congress of Bioethics was held on African soil for the first time in its 18-year history, underscoring how questions of justice, extraction, and representation are moving closer to the center of global research debate.
Those questions are especially sharp in genomics. African populations hold extraordinary human genetic diversity, and data generated on the continent have informed studies of disease risk, population history, and therapeutic development. But scientific value has not always translated into local value. In many cases, communities that contributed to research have had limited influence over how benefits are defined or distributed.
The model described in the Nature Communications paper pushes back on that pattern by giving communities more say over what counts as a meaningful outcome. That does not eliminate the wider structural inequalities in global health research, but it does create a more accountable framework within individual projects.
It also reframes benefit sharing as a governance issue rather than a charitable add-on. If communities help make research possible, then allocating resources to their priorities becomes part of responsible project management. In that sense, the 10% figure is not just a funding choice. It is a signal that ethical reciprocity can be formalized and measured.
Why researchers and funders may pay attention
The South African case could resonate well beyond genomics. Research organizations across health, data science, and biotechnology are under growing pressure to show that public-interest language is backed by concrete practices. Models that can be documented, costed, and replicated are more likely to influence funding rules than broad ethical aspirations alone.
For funders, the appeal is practical. A pre-defined benefit-sharing allocation makes expectations visible from the start. For universities and research units, it provides a template for translating ethics review into implementation. For industry partners, it offers a framework that may help avoid the reputational and community-relations problems that arise when research participants feel used but not included.
There are still open questions. The source material does not suggest that one percentage or one governance structure will fit every setting. Different communities may have different priorities, and researchers will need credible local processes to determine them. There is also the challenge of ensuring that community decision-making is genuinely representative and not captured by a narrow group of intermediaries.
Even so, the value of the South African work is that it turns a debate about ideals into a testable institutional practice. A model can be improved, challenged, or expanded. A vague promise cannot.
From principle to precedent
The strongest implication of this work is that benefit sharing may be entering a new phase. Rather than asking whether communities should share in the value of genomics research, the more practical question becomes how budgets, governance, and accountability should be structured to make that happen.
The researchers behind the paper are not presenting a final answer for all of science. What they are offering is a precedent: a way to embed listening, local choice, and material return inside the financial architecture of a research project.
That precedent could matter as genomic science expands and as more institutions seek data from historically underrepresented populations. If the South African model gains traction, it may help shift benefit sharing from an ethical aspiration discussed after studies are designed to a requirement built in before they begin.
- The model described at the World Congress of Bioethics allocates 10% of project budgets to community-chosen benefits.
- Examples cited in the source include school generators, water tanks, support for senior citizens, and youth-and-health community organizations.
- The approach was presented as a practical framework for researchers, universities, funders, and industry partners.
This article is based on reporting by Phys.org. Read the original article.
Originally published on phys.org
